Provided by Tiger Trade Technology Pte. Ltd.

COSMOS HEALTH INC

0.2124
-0.0091-4.11%
Volume:1.39M
Turnover:301.61K
Market Cap:21.45M
PE:-0.34
High:0.2280
Open:0.2270
Low:0.2089
Close:0.2215
52wk High:1.32
52wk Low:0.1616
Shares:101.00M
Float Shares:78.78M
Volume Ratio:0.73
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6172
EPS(LYR):-0.6321
ROE:-104.00%
ROA:-18.42%
PB:1.04
PE(LYR):-0.34

Loading ...

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

THOMSON REUTERS
·
Jun 15

Cosmos Health unit Cana receives contract manufacturing orders for 253,657 medicine units

Reuters
·
Jun 13

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

THOMSON REUTERS
·
Jun 13

Cosmos Health targets 2028 C-Scrub, C-Sept revenue of about $7.4 million

Reuters
·
Jun 12

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

THOMSON REUTERS
·
Jun 12

Cosmos Health CEO Grigorios Siokas reports acquisition of 701,447 common shares valued at $160,000

Reuters
·
Jun 12

Cosmos Health to acquire Doc Pharma, terms undisclosed

TIPRANKS
·
Jun 12

Cosmos Health - Enters Loi to Buy 100% of Doc Pharma

THOMSON REUTERS
·
Jun 12

Cosmos Health - Acquisition Expected to Be Immediately Accretive to Margins, Profitability, and Cash Flow

THOMSON REUTERS
·
Jun 12

Cosmos Health Signs Loi to Acquire Doc Pharma S.a., a European Gmp Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

THOMSON REUTERS
·
Jun 12

Press Release: Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Dow Jones
·
Jun 12

Cosmos Health secures 180-day extension to regain Nasdaq compliance

TIPRANKS
·
Jun 11

Cosmos Health wins Nasdaq extension to meet $1 minimum bid price by Dec. 7, 2026

Reuters
·
Jun 11

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

THOMSON REUTERS
·
Jun 11

Cosmos Health: Does Not Intend to Effect Reverse Stock Split Unless Necessary to Maintain Its Nasdaq Listing

THOMSON REUTERS
·
Jun 11

Cosmos Health Unit Signs 3-Year Manufacturing Deal With Verisfield

MT Newswires Live
·
Jun 11

Cosmos Health Signs 3-Year Contract Manufacturing Agreement With Verisfield for 3.9 Million Units of Vasclor Gest Progesterone Pessaries

THOMSON REUTERS
·
Jun 11

Cosmos Health unit Cana signs 3-year deal to make 3.9 million VASCLOR GEST progesterone pessaries for Verisfield

Reuters
·
Jun 11

Cosmos Health - Targets Over $200 Mln Revenue, $44.2 Mln Adj Ebitda, $92.3 Mln Equity by 2029

THOMSON REUTERS
·
Jun 10

Cosmos Health - Expects FY2026 Revenue to Surpass $90 Mln, up 38% Year-Over-Year

THOMSON REUTERS
·
Jun 10